세계의 원격 환자 모니터링 분야 AI 시장 : 컴포넌트별, 적응증별, 최종사용자별, 지역별 - 예측(-2030년)

The AI in remote patient monitoring market is projected to reach USD 8,438.5 million by 2030 from USD 1,967.7 million in 2024, at a high CAGR of 27.5% during the forecast period. Reason for growth in the AI in remote patient monitoring market: More individuals are getting hospital-acquired infections (HAIs) such as bloodstream infections, urinary tract infections, pneumonia, and infections caused by C. difficile. These infections have been associated with critical health complications and death in hospitals, hence the solutions that monitor patients remotely have been necessary in the prevention and management of risks. Further, the incidence of chronic diseases such as cardiovascular diseases, obesity, and diabetes is rising, which in turn increases the demand for effective remote monitoring technologies. The cost of healthcare in the US has substantially deteriorated; almost half of US adults are struggling to afford prescription drugs and doctor visits. According to US CDC about 1 in 31 hospital patients has at least one healthcare-associated infection. For instance, the University of Pittsburgh Medical Center reported that RPM devices reduced hospital readmissions by 76%.

"Wearable devices is the fastest growing segment in the AI in remote patient monitoring market by devices in 2023"

Wearable devices is expected to be the fastest-growing segment in the AI in remote patient monitoring market during 2023, due to the increasing acceptance of AI-enabled biosensors, smartwatches, and wearables for medical use. These devices are based on machine learning, deep learning, and continuous monitoring of vital signs, early detecting potential health issues, and supplying predictive insights. Other developments in AI-enabled ECG monitoring, glucose monitoring, and telehealth-enabling wearables are further supporting growth by increasing patient engagement and chronic disease management. For instance, in August 2024, Masimo's W1 Medical Watch received FDA 510(k) clearance to be incorporated into the Masimo SafetyNet Telemonitoring System for remote monitoring of health in real-time.

"North America dominated the remote patient monitoring market in 2023."

The AI in remote patient monitoring market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The North American region dominated the remote patient monitoring market because of several factors such as substantially high adoption rates of healthcare technologies, a robust and well-established infrastructure in healthcare, and constant growth in healthcare spending that supports such progress. In addition, the increasing trend in the chronic diseases patients suffer from and the increasing need for home healthcare solutions will also increase growth in this region's market. As of 2023, over 500 medical AI devices have undergone U.S. Food and Drug Administration (FDA) evaluation and received approval including RPM related medical devices.

The break-down of primary participants is as mentioned below:

• By Company Type - Tier 1: 40%, Tier 2: 35%, and Tier 3: 25%
• By Designation - C-level: 35%, Director-level: 40%, and Others: 25%
• By Region - North America: 45%, Europe: 30%, Asia Pacific: 20%, Latin America: 3%, and Middle East & Africa: 2%.

Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), OMRON Healthcare, Inc. (Japan), GE HealthCare (US), Medtronic (Ireland), AliveCor, Inc. (US), NIHON KOHDEN CORPORATION (Japan), F. Hoffmann-La Roche Ltd (Roche Diagnostics) (Switzerland), Beijing Choice Electronic Tech Co. Ltd (US), Biobeat (Israel), Biotronik (Germany), and AccurKardia, Inc. (US) are some of the key players in the AI in remote patient monitoring market.

• The study includes an in-depth competitive analysis of these key players in the AI in remote patient monitoring market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the AI in remote patient monitoring market by component (devices [wearable devices, implantable devices, handheld & portable devices, stationary devices]), software and services). By indication (oncology, cardiology, neurology, diabetes, sleep disorders, respiratory diseases, wellness improvement (weight management, fitness monitoring, hydration monitoring, nutritional tracking & monitoring, etc), mental health, and other indications (obstetrics, immunology, infectious diseases, ophthalmology, and others). By end user (healthcare providers [hospitals, ambulatory surgical centers, ambulatory care centers, and other outpatient settings, long term care & assisted living facilities, home healthcare, and other healthcare providers (diagnostics & imagining centers)], healthcare payers, patients, pharmaceutical & biotechnology companies, medTech companies, and other end users (employer groups, government organizations, academic institutes, research centers, and others)), and by region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in remote patient monitoring market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements. new product & service launches, regulatory approval, investment, fundings, mergers and acquisitions, and recent developments associated with the AI in remote patient monitoring market. Competitive analysis of upcoming startups in the AI in remote patient monitoring market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the AI in remote patient monitoring market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (growing telehealth and remote patient monitoring markets, rising prevalence of chronic diseases, growing adoption of mhealth apps, increased government support and favorable reimbursement policies, growing awareness about lifestyle management and home healthcare) restraints (regulatory variations across regions, shortage of skilled professionals to operate AI based tools, and data security concerns) opportunities (growing in the demand for personalized medicine, increase in the partnership and collaboration among healthcare providers and AI based companies, growing opportunities in emerging nations, hospital-at-home, and rising investment in AI based RPM solutions) challenges (issues related to accuracy due to scarcity of high quality healthcare data, reluctance among healthcare professionals to adopt AI in remote patient monitoring, and lack of interoperability)
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the AI in remote patient monitoring market
• Market Development: Comprehensive information about lucrative markets - the report analyses the AI in remote patient monitoring market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the AI in remote patient monitoring market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players such as Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), OMRON Healthare, Inc. (Japan), GE HealthCare (US), Boston Scientific Corporation (US), F. Hoffmann-La Roche Ltd (Roche Diagnostics) (Switzerland), NIHON KOHDEN CORPORATION (Japan), and Biotronik (Germany); among others in the AI in remote patient monitoring market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key sources of primary data
    • 2.1.2.2 Objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key insights from primary experts
    • 2.1.2.5 Breakdown of primary sources
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 SUPPLY-SIDE ANALYSIS
  • 2.2.2 BOTTOM-UP APPROACH (END-USER ADOPTION)
  • 2.2.3 TOP-DOWN APPROACH
  • 2.2.4 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
• 2.3 DATA TRIANGULATION
• 2.4 STUDY ASSUMPTIONS
  • 2.4.1 MARKET SIZING ASSUMPTIONS
  • 2.4.2 MARKET GROWTH ASSUMPTIONS
• 2.5 RISK ANALYSIS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AI IN REMOTE PATIENT MONITORING MARKET OVERVIEW
• 4.2 NORTH AMERICA: AI IN REMOTE PATIENT MONITORING MARKET, BY END USER AND REGION, 2023
• 4.3 AI IN REMOTE PATIENT MONITORING MARKET: GEOGRAPHIC SNAPSHOT
• 4.4 AI IN REMOTE PATIENT MONITORING MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Expanding telehealth and remote patient monitoring markets
    • 5.2.1.2 Increasing prevalence of chronic diseases
    • 5.2.1.3 Focus on development and adoption of mHealth applications
    • 5.2.1.4 Increased government support and favorable reimbursement policies
    • 5.2.1.5 Growing awareness about lifestyle management and home healthcare
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Regulatory variations across regions
    • 5.2.2.2 Shortage of skilled professionals to operate AI-based remote patient monitoring tools
    • 5.2.2.3 Data security concerns
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing demand for personalized medicines and care plans
    • 5.2.3.2 Increase in partnerships and collaborations among healthcare providers and AI-based companies
    • 5.2.3.3 Growth opportunities in emerging economies
    • 5.2.3.4 Rising investment in AI-based remote patient monitoring solutions
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Scarcity of high-quality healthcare data and privacy concerns
    • 5.2.4.2 Reluctance among healthcare professionals to adopt AI in remote patient monitoring devices
    • 5.2.4.3 Lack of interoperability
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.4 INDUSTRY TRENDS
  • 5.4.1 SHIFT TO VALUE-BASED AND PATIENT-CENTRIC CARE
  • 5.4.2 INNOVATIONS IN WEARABLE MEDICAL TECHNOLOGIES
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 ROLE IN ECOSYSTEM
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Wearable devices and sensors
    • 5.7.1.2 AI and ML
    • 5.7.1.3 Predictive analytics
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 mHealth applications
    • 5.7.2.2 Cloud computing
    • 5.7.2.3 Digital health platforms
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Point-of-care diagnostics
    • 5.7.3.2 Smart home health devices
• 5.8 TARIFF & REGULATORY ANALYSIS
  • 5.8.1 TARIFF ANALYSIS
    • 5.8.1.1 Tariff data for HS code 9018
    • 5.8.1.2 Tariff data for HS code 9021
    • 5.8.1.3 Tariff data for HS code 9022
  • 5.8.2 REGULATORY FRAMEWORK
    • 5.8.2.1 North America
    • 5.8.2.2 Europe
    • 5.8.2.3 Asia Pacific
    • 5.8.2.4 Middle East & Africa
    • 5.8.2.5 Latin America
  • 5.8.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.9 TRADE ANALYSIS
  • 5.9.1 TRADE ANALYSIS FOR HSN CODE 90189099
    • 5.9.1.1 Import data for HSN code 90189099
    • 5.9.1.2 Export data for HSN code 90189099
  • 5.9.2 TRADE ANALYSIS FOR HSN CODE 9021
    • 5.9.2.1 Import data for HSN code 9021
    • 5.9.2.2 Export data for HSN code 9021
  • 5.9.3 TRADE ANALYSIS FOR HSN CODE 9022
    • 5.9.3.1 Import data for HSN code 9022
    • 5.9.3.2 Export data for HSN code 9022
• 5.10 PRICING ANALYSIS
  • 5.10.1 INDICATIVE PRICING FOR AI-BASED REMOTE PATIENT MONITORING DEVICES, BY KEY PLAYER, 2023
  • 5.10.2 INDICATIVE PRICING FOR AI-BASED REMOTE PATIENT MONITORING DEVICES, BY REGION, 2023
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.11.2 BARGAINING POWER OF BUYERS
  • 5.11.3 THREAT OF SUBSTITUTES
  • 5.11.4 THREAT OF NEW ENTRANTS
  • 5.11.5 BARGAINING POWER OF SUPPLIERS
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 KEY BUYING CRITERIA
• 5.13 PATENT ANALYSIS
  • 5.13.1 PATENT PUBLICATION TRENDS
  • 5.13.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR AI-BASED REMOTE PATIENT MONITORING DEVICE PATENTS
  • 5.13.3 TOP PATENT OWNERS/APPLICANTS IN AI IN REMOTE PATIENT MONITORING MARKET
  • 5.13.4 LIST OF KEY PATENTS/PATENT APPLICATIONS
• 5.14 UNMET NEEDS & END-USER EXPECTATIONS
  • 5.14.1 UNMET NEEDS
  • 5.14.2 END-USER EXPECTATIONS
• 5.15 KEY CONFERENCES & EVENTS, 2025-2026
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 ADOPTION OF MEDTRONIC LINQ II WITH ACCURHYTHM AI FOR REMOTE PATIENT MONITORING
  • 5.16.2 ADOPTION OF ZETO EEG SOLUTIONS FOR NEUROLOGY AND EPILEPSY DIAGNOSIS
  • 5.16.3 ADOPTION OF DOZEE AI-POWERED BALLISTOCARDIOGRAPHY TECHNOLOGY
• 5.17 INVESTMENT & FUNDING SCENARIO
• 5.18 BUSINESS MODEL ANALYSIS
  • 5.18.1 SUBSCRIPTION-BASED MODELS
  • 5.18.2 PLATFORM-AS-A-SERVICE MODELS
  • 5.18.3 SERVICE-BASED MODELS
  • 5.18.4 FREEMIUM MODELS
  • 5.18.5 COLLABORATIVE ECOSYSTEM AND PARTNERSHIP MODELS
• 5.19 REIMBURSEMENT SCENARIO ANALYSIS

6 AI IN REMOTE PATIENT MONITORING MARKET, BY COMPONENT

• 6.1 INTRODUCTION
• 6.2 DEVICES
  • 6.2.1 WEARABLE DEVICES
    • 6.2.1.1 Rising adoption of consumer health technologies and growing trend toward preventive healthcare to drive segment
  • 6.2.2 IMPLANTABLE DEVICES
    • 6.2.2.1 Development of wireless communication technologies and advancements in medical devices to spur market adoption
  • 6.2.3 HANDHELD & PORTABLE DEVICES
    • 6.2.3.1 Rising consumer preference for home healthcare and self-monitoring to aid market growth
  • 6.2.4 STATIONARY DEVICES
    • 6.2.4.1 Reduced hospitalizations and improved patient outcomes through timely alerts to aid market growth
• 6.3 SOFTWARE
  • 6.3.1 EFFECTIVE TRANSFORMATION OF RAW DATA TO PERSONALIZED INSIGHTS FOR PATIENTS TO AUGMENT MARKET GROWTH
• 6.4 SERVICES
  • 6.4.1 INCREASING NEED FOR VALUE-BASED SPECIALIZED SERVICES TO BOOST MARKET GROWTH

7 AI IN REMOTE PATIENT MONITORING MARKET, BY INDICATION

• 7.1 INTRODUCTION
• 7.2 ONCOLOGY
  • 7.2.1 NEED FOR IMPROVED SYMPTOM MONITORING AND PERSONALIZED TREATMENT PLANS TO DRIVE MARKET
• 7.3 CARDIOLOGY
  • 7.3.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO FUEL MARKET GROWTH
• 7.4 NEUROLOGY
  • 7.4.1 GROWING ADOPTION OF TELEMEDICINE AND RISING NEED FOR CONTINUOUS MONITORING TO AID MARKET GROWTH
• 7.5 DIABETES
  • 7.5.1 HIGH ADOPTION OF AI-POWERED DEVICES FOR EFFECTIVE DIABETES MANAGEMENT TO PROPEL MARKET GROWTH
• 7.6 SLEEP DISORDERS
  • 7.6.1 AI-POWERED REMOTE PATIENT MONITORING DEVICES TO ENSURE EFFECTIVE SLEEP APNEA MANAGEMENT
• 7.7 RESPIRATORY DISEASES
  • 7.7.1 GROWING BURDEN OF COPD AND ASTHMA IN LOW- AND MIDDLE-INCOME COUNTRIES TO SUPPORT MARKET GROWTH
• 7.8 WELLNESS IMPROVEMENT
  • 7.8.1 RISING PREVALENCE OF OBESITY AND LIFESTYLE DISEASES TO AUGMENT MARKET GROWTH
• 7.9 MENTAL HEALTH DISORDERS
  • 7.9.1 AI-BASED REMOTE PATIENT MONITORING TO IMPROVE ACCESS TO MENTAL HEALTH SUPPORT AND REDUCE STIGMA OF IN-PERSON THERAPY
• 7.10 OTHER INDICATIONS

8 AI IN REMOTE PATIENT MONITORING MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HEALTHCARE PROVIDERS
  • 8.2.1 HOSPITALS
    • 8.2.1.1 Rising demand for high-quality care and increasing incidence of chronic diseases to drive market
  • 8.2.2 AMBULATORY SURGERY CENTERS, AMBULATORY CARE CENTERS, AND OTHER OUTPATIENT SETTINGS
    • 8.2.2.1 AI-driven remote patient monitoring devices to enhance postoperative care, patient safety, and recovery outcomes
  • 8.2.3 LONG-TERM CARE & ASSISTED LIVING FACILITIES
    • 8.2.3.1 Need for prolonged treatment for chronic diseases and high cost of hospital stays to fuel uptake
  • 8.2.4 HOME HEALTHCARE FACILITIES
    • 8.2.4.1 Increased preference for at-home treatment options to drive market
  • 8.2.5 OTHER HEALTHCARE PROVIDERS
• 8.3 HEALTHCARE PAYERS
  • 8.3.1 FAVORABLE REIMBURSEMENT SCENARIO FOR REMOTE PATIENT MONITORING SERVICES TO AUGMENT MARKET GROWTH
• 8.4 PATIENTS
  • 8.4.1 ADVANCEMENTS IN WEARABLE DEVICES AND PERSONALIZED PATIENT CARE TO FUEL MARKET GROWTH
• 8.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 8.5.1 AI-BASED REMOTE PATIENT MONITORING SOLUTIONS TO ASSIST PHARMA COMPANIES EXPAND MARKET PRESENCE
• 8.6 MEDTECH COMPANIES
  • 8.6.1 RISING DEMAND FOR ADVANCED TECHNOLOGIES FOR REMOTE DISEASE DIAGNOSIS AND TREATMENT TO FAVOR MARKET GROWTH
• 8.7 OTHER END USERS

9 AI IN REMOTE PATIENT MONITORING MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 US to dominate North American market during study period
  • 9.2.3 CANADA
    • 9.2.3.1 Need to curtail healthcare costs and high penetration of smartphones and tablets to drive market
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 High healthcare expenditure and increased preference for home monitoring to propel market growth
  • 9.3.3 UK
    • 9.3.3.1 Favorable government initiatives and high demand for advanced healthcare solutions to aid market growth
  • 9.3.4 FRANCE
    • 9.3.4.1 Increased adoption of connected medical devices to fuel market growth
  • 9.3.5 ITALY
    • 9.3.5.1 Increased government health expenditure and high geriatric population to boost market growth
  • 9.3.6 SPAIN
    • 9.3.6.1 Need to reduce healthcare costs and improve treatment quality to drive adoption of AI-based remote patient monitoring devices
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 Strong internet access and high smartphone adoption to augment market growth
  • 9.4.3 JAPAN
    • 9.4.3.1 Rising geriatric population and increasing government health expenditure to aid market growth
  • 9.4.4 INDIA
    • 9.4.4.1 Need to bridge gap between rural patients and urban doctors to propel market growth
  • 9.4.5 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Favorable government initiatives and increased health expenditure to favor market growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Technological advancements and favorable legal policies for digital health technologies to drive market
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Favorable government and non-government initiatives and increased investment in healthcare infrastructure to drive market
  • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS FOR AI IN REMOTE PATIENT MONITORING MARKET
• 10.3 REVENUE ANALYSIS, 2019-2023
• 10.4 MARKET SHARE ANALYSIS, 2023
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Component footprint
    • 10.5.5.4 Indication footprint
    • 10.5.5.5 End-user footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 10.6.5.1 Detailed list of key startups/SMEs
    • 10.6.5.2 Competitive benchmarking of key emerging players/startups
• 10.7 COMPANY VALUATION & FINANCIAL METRICS
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 BRAND/SOFTWARE COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS
  • 10.9.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 MEDTRONIC
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products/Services/Solutions offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product approvals
      • 11.1.1.3.2 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 KONINKLIJKE PHILIPS N.V.
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products/Services/Solutions offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches & approvals
      • 11.1.2.3.2 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 GE HEALTHCARE
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products/Services/Solutions offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 BOSTON SCIENTIFIC CORPORATION
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products/Services/Solutions offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Product launches
      • 11.1.4.3.2 Deals
      • 11.1.4.3.3 Expansions
      • 11.1.4.3.4 Other developments
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Right to win
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 OMRON HEALTHCARE, INC.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products/Services/Solutions offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product approvals & enhancements
      • 11.1.5.3.2 Deals
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Right to win
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 RESMED, INC.
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products/Services/Solutions offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product launches & enhancements
      • 11.1.6.3.2 Deals
      • 11.1.6.3.3 Expansions
      • 11.1.6.3.4 Other developments
  • 11.1.7 NIHON KOHDEN CORPORATION
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products/Services/Solutions offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches & approvals
      • 11.1.7.3.2 Deals
      • 11.1.7.3.3 Other developments
  • 11.1.8 F. HOFFMANN-LA ROCHE LTD. (ROCHE DIAGNOSTICS)
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products/Services/Solutions offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product launches & approvals
      • 11.1.8.3.2 Deals
  • 11.1.9 IRHYTHM INC.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products/Services/Solutions offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Product launches & approvals
      • 11.1.9.3.2 Deals
  • 11.1.10 BEIJING CHOICE ELECTRONIC TECH CO., LTD.
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products/Services/Solutions offered
  • 11.1.11 BIOTRONIK
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products/Services/Solutions offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Product launches & approvals
      • 11.1.11.3.2 Deals
  • 11.1.12 ALIVECOR, INC.
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products/Services/Solutions offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Product launches & approvals
      • 11.1.12.3.2 Deals
      • 11.1.12.3.3 Other developments
  • 11.1.13 MASIMO
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products/Services/Solutions offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product approvals & enhancements
    • 11.1.13.4 Recent developments
      • 11.1.13.4.1 Deals
  • 11.1.14 DEXCOM, INC.
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products/Services/Solutions offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Product launches & approvals
      • 11.1.14.3.2 Deals
  • 11.1.15 BIOBEAT
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products/Services/Solutions offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Product launches & approvals
      • 11.1.15.3.2 Deals
  • 11.1.16 TYTOCARE LTD.
    • 11.1.16.1 Business overview
    • 11.1.16.2 Products/Services/Solutions offered
    • 11.1.16.3 Recent developments
      • 11.1.16.3.1 Product enhancements
      • 11.1.16.3.2 Deals
      • 11.1.16.3.3 Other developments
  • 11.1.17 ZETO INC.
    • 11.1.17.1 Business overview
    • 11.1.17.2 Products/Services/Solutions offered
  • 11.1.18 GLOOKO, INC.
    • 11.1.18.1 Business overview
    • 11.1.18.2 Products/Services/Solutions offered
    • 11.1.18.3 Recent developments
      • 11.1.18.3.1 Product launches & enhancements
      • 11.1.18.3.2 Deals
      • 11.1.18.3.3 Other developments
  • 11.1.19 WELLDOC, INC.
    • 11.1.19.1 Business overview
    • 11.1.19.2 Products/Services/Solutions offered
    • 11.1.19.3 Recent developments
      • 11.1.19.3.1 Product approvals & enhancements
      • 11.1.19.3.2 Deals
  • 11.1.20 TURTLE SHELL TECHNOLOGIES PVT. LTD. (DOZEE)
    • 11.1.20.1 Business overview
    • 11.1.20.2 Products/Services/Solutions offered
    • 11.1.20.3 Recent developments
      • 11.1.20.3.1 Product approvals
      • 11.1.20.3.2 Other developments
• 11.2 OTHER PLAYERS
  • 11.2.1 BIOINTELLISENSE, INC.
  • 11.2.2 BLUE SPARK TECHNOLOGIES, INC.
  • 11.2.3 ACCURKARDIA, INC.
  • 11.2.4 AION BIOSYSTEMS, INC.
  • 11.2.5 BROOK INC.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS